Akademik Veri Yönetim Sistemi
VII.Turkey in vitro Diagnostic Symposia: Inflammation, İzmir, Türkiye, 27 - 29 Nisan 2022, cilt.34, ss.25
Objectives: Immunity and inflammatory response are the most
important features in cancer development, progression, and
survival. Prognostic significance of immune and inflammationrelated markers in neuroblastoma before and after treatment and
during the follow-up period has not been adequately investigated.
The aim of this study is to investigate the prognostic importance
of immune and inflammation-related markers in neuroblastoma.
Materials-Methods: In 1750 neuroblastoma cases examined
between 2012-2022, achievable blood albumin, CRP values and
ratio (Glascow Prognostic score), diversity and amount of
immune cell infiltration in tumor tissue and surrounding tissue,
immunohistochemical CTLA-4, PDL-1, PD-1, PDL-2
expression was evaluated. RESULTS were tested with analysis
of variance and survival at p<0.05 significance.
Results: The mean age of the cases was 36.23±39.90 (1-217
months) and 48.6% were girls and 51.4% were boys. 28% of the
cases are in low risk, 23.3% in medium risk, 48.7% in high-risk
class. Lymphocyte infiltration was detected in 6% and a low
number in neuroblastoma cases before treatment. No
heterogeneity was detected in the expression of CTLA-4, PDL1,
PD1. After multimodal chemotherapy, lymphocyte infiltration
was found significantly more in tissues with differentiated
ganglioneuroma. It was noted that immunity did not show
intertumoral heterogeneity.
Conclusions: Neuroblastoma was found to be weak in immune
and inflammatory response. Absence of intratumoral
heterogeneity in immune response, increased immune cell
increase after chemotherapy were interpreted in favor of
metachronous immune heterogeneity. In vitro, ex vivo and in
vivo studies are needed to determine the immune profile changes
in tumors after radiotherapy and chemotherapy, in short, whether
neuroblastomas can be converted from cold tumors to hot tumors
for immunotherapy.
Keywords: Neuroblastoma, heterogeneity, immune response,
inflamatory response